Fed Up With the Healthcare Industry, This Red State Capped Insulin Prices for Patients

Hillsboro, North Dakota - The Kritzberger family traces its roots to farming in the Red River Valley for over a century. They now cultivate sugar beets, soybeans, and grains, often struggling to balance their finances. Ang Kritzberger expressed the family's financial burden during a recent autumn morning. For the past decade, their daughter Nina, diagnosed with Type 1 diabetes at age seven, has been a source of additional concern, pushing the family into a nationwide debate on safeguarding patients from exorbitant insulin costs.

Nina's diagnosis required her mother to monitor her every two hours, day and night, for the first 60 days. The family bears a substantial financial burden, paying around $8,000 yearly for medical expenses, including drugs, supplies, and appointments. This is not an isolated case. Prolonged high insulin prices have forced diabetic individuals to cut back on medication, leading to dire consequences in some instances.

However, a growing movement across the nation aims to cap the amount patients with diabetes pay for insulin. This initiative has brought together Democrats and Republicans, forming an emerging consensus that the government should shield individuals from high drug prices. North Dakota state Senator Sean Cleary, a Republican, co-sponsored legislation last year to cap patients' insulin bills at $25 a month.

North Dakota is among 29 states that have implemented such measures. The cap limits the amount patients must pay out-of-pocket each month for insulin, regardless of their high deductible, which might require them to pay thousands of dollars before other healthcare coverage, such as doctor visits, hospitalizations, or other prescriptions, becomes effective.

Patient advocates, including the American Diabetes Association, have been advocating for out-of-pocket caps and other protections in response to surging insulin prices and reports of patients dying due to financial constraints. Approximately one-fifth of the estimated 40 million Americans with diabetes rely on insulin. Though insulin prices have moderated slightly since the drug companies faced public backlash, the average yearly out-of-pocket costs for those with private insurance have remained high.

For families like the Kritzbergers, a government cap offers a protective shield against potential price hikes and provides some relief from the anxiety of managing a severe medical condition.